H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

  • ID: 2081856
  • SWOT Analysis
  • 58 pages
  • GlobalData
  • H. Lundbeck A/S
1 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Novo Nordisk AS
  • Pfizer Inc
  • Sanofi
  • MORE
H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of the central nervous system (CNS) diseases including psychiatric and neurological disorders. Its products are indicated for the treatment of diseases such as Alzheimer's disease, depression, Parkinson's disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington's disease, among others. The company operates production facilities in Denmark, France, Italy and China and research centers in China and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies and hospitals in Europe, the US and other countries. Lundbeck is headquartered in Valby, Denmark.

H. Lundbeck AS Key Recent Developments

Jul 02, 2018: H. Lundbeck Appoints Dr. Deborah Dunsire As President And CEO
Jun 06, 2018: Lundbeck reaches voluntary agreement in principle with U.S. Department of Justice
May 22, 2018: Lundbeck divests preclinical research programs
May 08, 2018: Lundbeck realized 14% growth in revenue (local currency) and 103% growth in EPS
Mar 20, 2018: Lundbeck held its Annual General Meeting on 20 March 2018 at the company's registered office

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Novo Nordisk AS
  • Pfizer Inc
  • Sanofi
  • MORE
Section 1 - About the Company
  • H. Lundbeck AS - Key Facts
  • H. Lundbeck AS - Key Employees
  • H. Lundbeck AS - Key Employee Biographies
  • H. Lundbeck AS - Major Products and Services
  • H. Lundbeck AS - History
  • H. Lundbeck AS - Company Statement
  • H. Lundbeck AS - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • H. Lundbeck AS - Business Description
  • Product Category: Abilify Maintena
  • Overview
  • Performance
  • Product Category: Brintellix/Trintellix
  • Overview
  • Performance
  • Product Category: Cipralex/Lexapro
  • Overview
  • Performance
  • Product Category: Northera
  • Overview
  • Performance
  • Product Category: Onfi
  • Overview
  • Performance
  • Product Category: Other pharmaceuticals
  • Performance
  • Product Category: Other Revenue
  • Performance
  • Product Category: Rexulti
  • Overview
  • Performance
  • Product Category: Sabril
  • Overview
  • Performance
  • Product Category: Xenazine
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Target Markets
  • Performance
  • Geographical Segment: International Markets
  • Target Markets
  • Performance
  • Geographical Segment: Other revenue
  • Performance
  • Geographical Segment: The US
  • Target Markets
  • Performance
  • R&D Overview
  • H. Lundbeck AS - Corporate Strategy
  • H. Lundbeck AS - SWOT Analysis
  • SWOT Analysis - Overview
  • H. Lundbeck AS - Strengths
  • H. Lundbeck AS - Weaknesses
  • H. Lundbeck AS - Opportunities
  • H. Lundbeck AS - Threats
  • H. Lundbeck AS - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • H. Lundbeck AS, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jun 06, 2018: Lundbeck reaches voluntary agreement in principle with U.S. Department of Justice
  • May 22, 2018: Lundbeck divests preclinical research programs
  • May 08, 2018: Lundbeck realized 14% growth in revenue (local currency) and 103% growth in EPS
  • Mar 20, 2018: Lundbeck held its Annual General Meeting on 20 March 2018 at the company's registered office
  • Feb 07, 2018: Lundbeck delivers its best financial results following 10% revenue growth and 117% growth in net profit
  • Dec 02, 2017: Study Evaluates Refractory Epilepsy Screening Tool for LGS (REST-LGS)
  • Nov 08, 2017: Lundbeck increased operating profit (EBIT) with 126% and EPS by 182% in the first nine months of 2017
  • Oct 30, 2017: Changes to Lundbeck’s Executive Management
  • Oct 05, 2017: Neurological-Focused pharmaceutical company, Lundbeck, Continues Use of Medidata Clinical Cloud with Multi-Year Partnership
  • Sep 11, 2017: Changes in Executive Management in Lundbeck
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • H. Lundbeck AS, Key Facts
  • H. Lundbeck AS, Key Employees
  • H. Lundbeck AS, Key Employee Biographies
  • H. Lundbeck AS, Major Products and Services
  • H. Lundbeck AS, History
  • H. Lundbeck AS, Subsidiaries
  • H. Lundbeck AS, Key Competitors
  • H. Lundbeck AS, Ratios based on current share price
  • H. Lundbeck AS, Annual Ratios
  • H. Lundbeck AS, Annual Ratios
  • H. Lundbeck AS, Annual Ratios
  • H. Lundbeck AS, Interim Ratios
  • H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • H. Lundbeck AS, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • H. Lundbeck AS, Performance Chart (2013 - 2017)
  • H. Lundbeck AS, Ratio Charts
  • H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • H. Lundbeck AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Sanofi
  • Pfizer Inc
  • Novo Nordisk AS
  • Johnson & Johnson
  • GlaxoSmithKline Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll